key: cord-0426238-3sqrhbcp
authors: Domingo-Sabugo, C.; Willis-Owen, S. A. G.; Mandal, A.; Nastase, A.; Dwyer, S.; Brambilla, C.; Hector Galvez, J.; Zhuang, Q.; Popat, S.; Eveleigh, R.; Munter, M.; Lim, E.; G. Nicholson, A.; Lathrop, M.; Cookson, W. O. C.; Moffatt, M. F.
title: Distinct pancreatic and neuronal Lung Carcinoid molecular subtypes revealed by integrative omic analysis
date: 2021-07-30
journal: nan
DOI: 10.1101/2021.07.27.21260865
sha: b28fc148913499f7fb2de9c67aec2dc62dd9332f
doc_id: 426238
cord_uid: 3sqrhbcp

Lung Carcinoids (L-CDs) are uncommon low-grade neuroendocrine tumours that are only recently becoming characterised at the molecular level. Notably data on the molecular events that precipitate altered gene expression programmes are very limited. Here we have identified two discrete L-CD subtypes from transcriptomic and whole-genome DNA methylation data, and comprehensively defined their molecular profiles using Whole-Exome Sequencing (WES) and Single Nucleotide Polymorphism (SNP) genotyping. Subtype (Group) 1 features upregulation of neuronal markers (L-CD-NeU) and is characterised by focal spindle cell morphology, peripheral location (71%), high mutational load (P=3.4x10-4), recurrent copy number alterations and is enriched for Atypical Lung Carcinoids. Group 2 (L-CD-PanC) are centrally located and feature upregulation of pancreatic and metabolic pathway genes concordant with promoter hypomethylation of beta cell and genes related to insulin secretion (P<1x10-6). L-CD-NeU tumours harbour mutations in chromatin remodelling and in SWI/SNF complex members, while L-CD-PanC tumours show aflatoxin mutational signatures and significant DNA methylation loss genome-wide, particularly enriched in repetitive elements (P<2.2 x 10-16). Our findings provide novel insights into the distinct mechanisms of epigenetic dysregulation in these lung malignancies, potentially opening new avenues for biomarker selection and treatment in L-CD patients.

Lung carcinoids (L-CDs) are rare, slow growing neuroendocrine tumours that represent 2% of all lung cancers 1 and mutational studies that have shown similar genes to be altered across NENs, but differences between NECs and NETs, and within SCLC, LCNEC and NETs themselves, although at different prevalences between NETs, with the lowest number of molecular alterations in L-CDs [5] [6] [7] [8] [9] .

Lung carcinoids remain relatively understudied despite their increasing incidence 10-16 .

Although many patients with rare NETs can be cured by resection, management of advanced disease remains problematic 17 , and clinically experience no clear pathway of care in their cancer journey, with their tumours difficult to diagnose and treat and patients lacking disease specific support 18 . Disagreement exists over the optimal diagnosis 2 and there is inter-observer variability in differentiating TCs from ACs 19 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint To date no lung carcinoid studies have investigated DNA methylation alterations at a genomic scale or have integrated genetic, transcriptomic and clinical data. We therefore describe here a comprehensive characterization of these malignancies at the molecular level.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint

Unsupervised clustering and Principal Components Analysis (PCA) analysis of RNA sequencing data from 15 LCAR tumours (comprising 3 ACs and 12 TCs) clearly differentiated tumours into two approximately equally sized groups (n=8 and 7 respectively). These two groups were reproducibly identified using data from the top 500 most variable genes or all sequenced genes (n 25,764) (Supplementary Fig. 1a showing the strongest evidence of differential expression, both with relatively raised expression in this group, were TM4SF5 (log2FC 10.50, adj.P=3.39x10 -10 ) and HNF1A (log2FC 8.33, adj.P=3.39x10 -10 ). TM4SF5 is a known tumorigenic factor in several cancer types, including liver, colon, pancreatic and esophageal cancers [20] [21] [22] [23] [24] [25] , whilst HNF1A encodes a putative master regulator of human pancreatic cancer stem cell properties 26 . The APOBEC1 complementation factor (A1CF) showed the highest log2 fold change (log2FC) in expression as compared to Group 2, suggesting that A1CF protein expression could be used as a molecular marker.

Group 2 showed upregulation of pathways involved in neuronal differentiation, peaking at serotonin neurotransmitter release cycle (NES -1.79, P=0.004). In line with this pattern, we observed significantly higher expression levels of various neuronal genes in this group (Supplementary Data 1). ASCL1 for example, encodes a neuronal differentiation transcription factor and is a lineage-specific oncogene for high-grade neuroendocrine lung cancer 27,28 , whilst SLIT1, ROBO1 and SRGAP1 all represent members of the cell signalling protein complex slit/robo . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint which is involved in axon guidance and angiogenesis. In addition, FAM3B/PANDER, a pleiotropic secreted cytokine that induces apoptosis in insulin-secreting beta-cells 29 was highly expressed in Group 2 (log2FC 6.21, adj.P=1.76x10 -5 ). PANDER is expressed ubiquitously, including lung 30 and some neurons of the brain 31 , and it has recognised roles in invasiveness and tumorigenicity when overexpressed in prostate 32 and colon 33 cancers.

On the basis of these features, from this point onwards we refer to Group 1 as LCAR-NeU and Group 2 as LCAR-PanC. Fig. 3a ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint This is consistent with a higher mean number of mutations detected in ACs, and tumours from this histology all falling in the LCAR-NeU molecular group.

A different spectrum of COSMIC Mutational Signatures (CMS) was consistently observed between the two LCAR groups; 50% of LCAR-PanC samples possessed an aflatoxin exposure signature. This is consistent with our differential gene expression data, in which several genes (GGT5, CYP34A, CYP3A5 and DPEP1) participating in aflatoxin activation and detoxification were expressed at significantly higher levels in PanC tumours.

On the other hand, LCAR-NeU samples variably showed a CMS 5 signature (57%), which is found in most cancer samples, and/or a CMS 8 signature (43%), which is associated with double strand break repair by homologous recombination. A summary of the mutational signatures is given in Supplementary Figure 4a Fig. 5) . These data confirm a biological distinction between the two observed LCAR subtypes.

The most frequently mutated genes in L-CD-NeU were components of the cytoskeleton (57%), including ITGA1, ITGA2, PLEC and TPJ1, and histone covalent modifiers (43%) (JMJD1C, KDM1B and KDM4E) (Fig. 3) . By contrast, L-CD-PanC tumours showed mutations in ARID1A and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint ARID5B (25%), both members of the SWI/SNF complex; and the Notch signalling genes PLXND1 and/or WWC1 (25%). Notch signalling controls cell fate decisions and has previously been found to be activated in neuroendocrine cells undergoing reprogramming after injury 35 and CNAs is given in Figure 4 with information regarding genes in significant cytobands and the percentages for CNAs in each subtype are detailed in Supplementary Table 2 .

Similar to mutations, L-CD-NeU showed higher frequencies of CNAs, with 71.43% of tumours harbouring KIF20B deletions, a kinesin involved in neuron polarization 37 . In contrast with earlier studies 38 , we did not detect any significant loss in RB1, TP53 and MEN1 or any significant gains in TERT, SDHA or RICTOR.

Aberrant DNA methylation is a common feature of cancer and provides a mechanism of gene expression dysregulation. Here we applied whole genome bisulfite sequencing (WGBS) to generate a snapshot of the DNA methylation profile in tumour and matched histologically normal tissue. Mirroring our observations from transcriptomic data, PCA of genome-wide DNA methylation data differentiated L-CD-NeU from L-CD-PanC tumours (Fig. 4a) . We identified 4,304 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. Table 3 ). We therefore sought to investigate the properties of DNA methylation alterations in the non-coding genome of the two L-CD groups. PCA analysis of different genomic regions' DNA methylation levels revealed that repeated elements explained most of the variance (26.89%) and alone distinguished L-CD-NeU from L-CD-PanC (Fig. 4b) .

Reactivation of transposable elements (TE) through epigenetic mechanisms is an established feature of some cancers with roles in tumour immunity 41 . We found here a significant enrichment of TEs in hypomethylated DMRs (relative enrichment = 1.31, 95% CI 1. 16 Fig. 6 ). Repeat elements and non-genic CpG sites are known to lose methylation during aging 42 , nevertheless, we found no significant difference in age between LCAR subtypes.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint

In this study we have identified two distinct molecular subtypes of L-CDs from RNAsequencing data; L-CD-NeU and L-CD-PanC, and characterised their molecular profiles using WES, SNP genotyping and WGBS. We have shown that these two groups differ significantly in their transcriptional, mutational and epigenetic profiles, as well as their physical characteristics.

Differential analysis of gene expression data showed upregulation of metabolic pathways and hallmarks of pancreatic beta cells in PanC tumours, whereas pathways related to the neuronal system, neurotransmitter synthesis and release were found enriched in NeU tumours. Differential expression between these two groups was most marked with TM4SF5, notable since TM4SF5targeted monoclonal antibody and peptide vaccination has previously established preventive and/or therapeutic effects in hepatocellular carcinoma, colon cancer and pancreatic cancer models 25 . On the basis of these data, assessment of anti-hTM4SF5 antibody treatment efficacy in TM4SF5-expressing PanC L-CDs may be warranted.

In our transcriptomic data, A1CF showed the highest log2 fold-change expression between the two L-CD groups suggesting that A1CF protein expression may have utility as a molecular marker for anti-hTM4SF5 antibody therapy. Furthermore, we show that the NeU L-CD classification is significantly associated with a focal spindle cell morphology and peripheral tumour location, meaning that these physical features may provide a minimally invasive, accessible proxy, in agreement with the distinct characteristics of central and peripheral carcinoids reported by George et al 43 . Additionally, FAM3B/PANDER expression has been detected at the protein level and its inhibition has shown antitumour effects in vitro in prostate and several human cancer lines 30 , suggesting therapeutic potential and a marker for the differential diagnosis of L-CD subtypes in combination with TM4SF5 and A1CF protein expression.

Molecular profiling of L-CDs have previously shown chromatin remodelling genes, such as MEN1, ARID1A, PSIP1, KMT2C and KMT2A, to be recurrently mutated in L-CDs while TP53, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint RB1 and STK11 mutations have been found frequently altered in non-carcinoid NETs 44 . Other studies have emphasized the distinction between TCs and ACs, and molecular events distinguishing these subtypes are reported to affect the genes MEN1, TP53, KMT2C, TERT, SDHA, RICTOR and RB1 6 . In our study we did not detect any mutation or CNA in any of these genes, in contrast with earlier studies 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint

Here we observed predominance of C→A mutations in the L-CD-PanC group ( Supplementary   Fig. 3b ). High levels of AFB1 can be present in respiratory grain-dust particles 55,56 , and as such could potentially contribute to L-CD-PanC carcinogenesis. Controlled experiments designed to detect and define any role of aflatoxin in L-CD-PanC pathogenesis should be a priority for future investigation.

The mutational landscapes of L-CDs alone could not explain the transcriptomic differences detected and so we analysed their DNA methylomes by using WGBS data. We identified DMRs in promoters of pancreatic beta cells and genes related to insulin secretion in L-CD-PanCs, as well as mismatch repair genes, pinpointing DNA methylation changes as a key event in this cancer group.

TE-enriched regions showed significant hypomethylation in L-CD-PanCs and alone were sufficient to differentiate from L-CD-Neu tumours by PCA analysis. This suggests that epigenetic dysregulation in the non-coding genome may be a major contributor to the PanC subtype.

Significantly higher expression levels of A1CF in L-CD-PanC tumour genomes may contribute to this generalised hypomethylation. A1CF serves as a docking site to recruit APOBEC1 deaminase, which has a role in active DNA demethylation followed by T:G mismatch repair 57,58 . Altogether these findings highlight the value of whole-genome data to better understand and refine the molecular alterations in these malignancies.

We recognise a number of limitations of our study. The relative rarity of L-CD tumours and access to fresh frozen tissue has meant that our sample size is fairly small. Histopathological analyses with the markers we have identified could validate the observed classifications and should be a priority for future studies to enable translation into a clinical setting.

The distinct clinical phenotypes associated with these molecular subtypes suggest novel biomarkers for patient stratification. Our findings could be used to refine and complement the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint current WHO classification of lung carcinoids and will stimulate further investigation to improve the cancer journey of patients with L-CD . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint Figure 5 : Genes with promoters showing significant differential methylation between L-CD molecular groups. Figure 5 : Genes with promoters showing significant differential methylation between L-CD molecular groups. Statistical analysis was performed using a Wald test and P<1x10 -6 was considered statistically significant. Only DMRs with a methylation difference of >20% between the two groups were considered for annotation.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint 0.7). Differential Expression (DE) analysis was modelled using limma (ver. 3.42.2) and the empirical Bayes method. P-values were adjusted using a Benjamini Hochberg method to control the FDR below 1%.

The Gene Set Enrichment Analysis (GSEA) (ver. 4.0.3) software was utilised to detect significant group-wise differences in a Reactome Canonical Pathways Gene Set 60 . In the setting of exploratory discovery, we used a less conservative FDR of 0.25 and nominal P-value of 0.01.

WES and mutation calling was performed at the McGill Genome Centre, Montreal, Canada.

Sequencing libraries were prepared with the SureSelect XT Target Enrichment System (Agilent SureSelect Human All Exon V4) and sequenced with 100bp Paired-End Illumina HiSeq2000

Sequencer.

Processing and variant calling of the WES data was performed using the analysis piepeline "GenPipes" 61 . In short, Fastq files were trimmed and aligned against the Human Genome December 2013 Assembly (GRCh37/hg19) with BWA mem. SAM files thus obtained per sample were sorted by chromosomic location with GATK (Genome Analysis Tool Kit) (ver.3.7) and read alignments deemed to be PCR duplicates were removed with Picard (ver. 2.9.0). Pre-processing involved local realignment around known insertions/deletions (InDels) and Base Quality Score Recalibration (BQSR) with GATK (ver. 3.7). Somatic mutations and InDels were called with MuTect (ver. 1.16) and Scalpel (ver. 0.4.1) software, respectively. Somatic calls were then combined, and subsequent steps involved decomposing multiallelic variants from VFC files, genetic variant annotation and functional effect prediction with SnpEff (ver. 4.3) and addition of metadata with Genome MINIng (GEMINI) (ver. 0.14-0.20) software. The annotated variants were filtered based on known impact predictions and CADD scores. We considered pathogenic somatic variants as those with predicted high or medium impact, and those assigned a minimum CADD score of 15 and not flagged as polymorphic.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint

Neuroendocrine tumors of the lung

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

Thoracic Tumours: WHO Classification of Tumours

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D

New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database

One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

The epidemiologic trends of neuroendocrine tumors in Taiwan : an updated analysis of a nation-wide population-based study

Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes

Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971

Predictors of survival in 211 patients with stage IV pulmonary and gastroenteropancreatic MIBG-Positive neuroendocrine tumors treated with 131I-MIBG

Patient experiences of having a neuroendocrine tumour: A qualitative study

Interobserver variability for the WHO classification of pulmonary carcinoids

Identification of a new tumour-associated antigen TM4SF5 and its

We thank the patients for participating to our study. We also thank Dr. Alain Pacis and Paul Stretenowich for their help with the analysis of WGBS data. This study was supported by the Asmarley Trust and by the Wellcome Trust. Sample collection for this study was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust. The funding sources had no role in study design, collection, analysis and interpretation of the data, or in the writing of the manuscript.

The R (ver.3.6.1) DeconstructSigs package (ver. 1.8.0) was used to determine the contribution of known mutational processes in L-CD samples. Signature matrices were calculated based on the fraction of times a mutation was seen in each of the 96-trinucleotide context for each COSMIC catalogued signature (v2). The exome2genome normalisation method was used to reflect the absolute frequency of each nucleotide context as it would across the whole genome. As a result, a reconstructed mutational profile was obtained based on the final weights for each individual sample.

Illumina Infinium OmniExpressExome (v1.6) arrays were used for genotyping of > 900,000 SNP markers in 15 tumour and normal matched L-CD samples. The processing and Quality Control were performed with GenomeStudio (ver. 2.0.4). SNPs in pseudo-autosomic regions and InDels were filtered out.To improve accuracy of copy number variant detection ASCAT (v.2.5.2) was separately applied in tumour and normal samples for GC bias correction. DNACopy (v.1.56.0) was used to segment copy number data into regions of estimated equal copy number. Regions with >10 markers support were used for calling CNAs with Gistic2 (ver. 2.0.23). Germline Copy Number Variants (CNVs) were first identified on normal lung tissue samples and were subtracted from the tumour segmented data before CNA calling. Copy number data was visualised using Maftools (ver. 1.9.30).

WGBS libraries were constructed using the KAPA High Throughput Library Preparation Kit (Roche/KAPA Biosystems) from 1ug of the sperm DNA spiked with 0.1% (w/w) unmethylated lambda and pUC19 DNA (Promega). DNA was sonicated (Covaris) and fragments . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. were used to sort by chromosomal location and for the removal of PCR duplicates. The bismark methylation extractor was used to extract methylation in CpG context. Bis-SNP was used to identify SNPs and insertion/deletion events (InDels) that were subsequently filtered out with Bedops (ver.

Normalisation of the processed WGBS data was carried out with the methylKit R package (ver. 1.12.0). Finally, Dispersion Shrinkage for Sequencing data with single replicates (DSS-single) implemented in the DSS Bioconductor R package (ver. 2.34.0) was used for calling of Differentially Methylated Regions (DMRs) to account for spatial correlation, read depth and biological variation between groups. Specifically, a smoothing span of 500 bps was used to improve estimation of methylation levels by accounting for nearby CpG sites. A Wald statistical test was then performed for . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint CpGs with at least 10% difference between tumour and normal, and the difference was considered significant when P-value <1x10 -6 . Regions a minimum of 50 bps in length with at least 3 significant CpGs were identified as DMRs and merged when co-localised by less than 50 bps. Finally, only DMRs with an absolute tumour:normal methylation difference exceeding 20% were selected for further analysis. DMRs were annotated into different categories with the annotatr R package (ver. 1.12.1).. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint submitted work. In addition, EL has patents P52435GB and P57988GB issued to Imperial Innovations, is the Director of lung screening at the Cromwell Hospital.

Genotyping and sequencing data generated will be submitted at the EGA European Genome-Phenome Archive (EGA) (https://ega-archive.org/) under accession code: EGAS00001005473.

Supplementary Material is available for this paper.

Correspondence and requests for materials should be addressed to w.cookson@imperial.ac.uk or m.moffatt@imperial.ac.uk . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21260865 doi: medRxiv preprint